Teva and Cancer Research Technology agree oncology alliance

Teva has entered into a new collaboration with Cancer Research Technology to research and develop promising new oncology agents.

The alliance will focus on the creation of first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells, a key process that helps tumours to resist the effects of chemotherapy and develop resistance to treatment.

Cancer Research Technology is the technology development arm of charity group Cancer Research UK, which has created a world-class hub of expertise in DDR-related basic, translational and clinical research in Britain.

Teva will be able to leverage the expertise of some of the UK's leading universities through this new collaboration, as well as its own proven drug research and development capabilities.

Dr Michael Hayden, president of Teva's global research and development and chief scientific officer, said: "For cancer patients, it is important that we maintain the momentum of progress that has been made in oncology in recent years."

This comes after the company agreed another cancer research alliance with Champions Oncology earlier this month.